Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
J
Jennifer S. Guimbellot
Associate Professor
Also affiliated: University of North Carolina at Chapel Hill (2013); Arkansas Children's Hospital (2025); University of Alabama (2018); University of Washington (2023); University of Arkansas Medical Center (2025–2026); University of Alabama at Birmingham (2003–2026); University of North Carolina Hospitals (2013); UAB Medicine (2017–2026); Arkansas Children's Research Institute (2024–2026)
20 h-index
70 pubs
1,035 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Jennifer S. Guimbellot's research focuses on cystic fibrosis (CF), particularly investigating the expression and function of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. Her work has explored the role of oxygen availability in CFTR expression and the intracellular processing of the endogenous CFTR protein in epithelial cell lines. Guimbellot has also examined the long-term clinical effectiveness of CFTR modulator therapies, such as ivacaftor, and the use of novel therapeutic development platforms like human nasal epithelial organoids. Her publication record includes studies on microRNA levels and their correlation with mRNA through microarray analysis, as well as a study on the epidemiology and clinical outcomes of tracheostomy in children. Guimbellot has a scholarly impact indicated by an h-index of 19, with over 70 publications and more than 1,000 citations. She has established collaborative relationships with A. Chalamalla and Saly Abouelenein at the University of Arkansas for Medical Sciences, with whom she shares numerous publications.
Metrics
- h-index: 20
- Publications: 70
- Citations: 1,035
Positions
-
Associate Professor publications 2024–2026University of Arkansas for Medical Sciences Institutional directory
-
University of Arkansas for Medical Sciences publications 2024–2026ORCID
Selected Publications
-
Shifting Nutrition Paradigms: Changing Attitudes Towards Diet and Body Perceptions Among People With CF in the Era of Highly Effective Modulators (2026)
-
Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis (2026)
-
Generic and Biosimilar Prescribing in Children and Adolescents: Policy Statement (2026)
-
Generic and Biosimilar Prescribing in Children and Adolescents: Technical Report (2026)
-
Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy (2026)
-
Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches (2025)
-
Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches (2025)
-
Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches (2025)
-
EPS2.03Highly-effective CFTR modulation and lung development by age, gender, and height among children with cystic fibrosis (2025)
-
P018 Single measurement quantification and modeling of elexafactor, tezacaftor and ivacaftor in adults: overlap between full and reduced dosing (2025)
-
One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators (2025)
-
Tobacco Smoke Exposure Decreases Longitudinal Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (2025)
-
Modulator Concentrations Significantly Contribute to Variability in Sweat Chloride Results After Therapy With Elexacaftor/Tezacaftor/Ivacaftor (2025)
-
Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant (2025)
-
Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial (2024)
Collaboration Network
Top Collaborators
A. Chalamalla
University of Alabama at Birmingham
8 shared publications
In database
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
- EPS2.03Highly-effective CFTR modulation and lung development by age, gender, and height among children with cystic fibrosis
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
Showing 5 of 8 shared publications
Natalie R. Rose
University of Alabama at Birmingham (US)
6 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
- Literary evidence of the impact of nonbiological risk factors on CRMS/CFSPID: A scoping review
- Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy
- Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis
Showing 5 of 6 shared publications
Saly Abouelenein
University of Arkansas for Medical Sciences
6 shared publications
In database
- Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
- P018 Single measurement quantification and modeling of elexafactor, tezacaftor and ivacaftor in adults: overlap between full and reduced dosing
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
Showing 5 of 6 shared publications
Edward P. Acosta
University of Alabama at Birmingham (US)
5 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial
- Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
- Modulator Concentrations Significantly Contribute to Variability in Sweat Chloride Results After Therapy With Elexacaftor/Tezacaftor/Ivacaftor
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
Elizabeth Baker
University of Alabama at Birmingham (US)
5 shared publications
- Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
- Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant
- Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
- Modulator Concentrations Significantly Contribute to Variability in Sweat Chloride Results After Therapy With Elexacaftor/Tezacaftor/Ivacaftor
- EPS2.03Highly-effective CFTR modulation and lung development by age, gender, and height among children with cystic fibrosis
Kevin J. Ryan
University of Alabama at Birmingham (US)
4 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant
- Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
- Modulator Concentrations Significantly Contribute to Variability in Sweat Chloride Results After Therapy With Elexacaftor/Tezacaftor/Ivacaftor
Kathleen J. Ramos
University of Washington (US)
4 shared publications
- One- and Two-timepoint Sparse Sampling is Highly Predictive of Average Plasma Concentration of CFTR Modulators
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
Alexander E. Dowell
University of Alabama at Birmingham (US)
2 shared publications
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
- Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia
Steven M. Rowe
Cystic Fibrosis Foundation (US)
2 shared publications
- Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial
- Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
S. Vamsee Raju
Cystic Fibrosis Foundation (US)
2 shared publications
- Ivacaftor for Chronic Obstructive Pulmonary Disease: Results from a Phase 2, Randomized Controlled Trial
- Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
Gabriela R. Oates
University of Alabama at Birmingham (US)
2 shared publications
- Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL)
- Tobacco Smoke Exposure Decreases Longitudinal Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis
Lloyd J. Edwards
Alabama Department of Public Health (US)
2 shared publications
- EPS2.03Highly-effective CFTR modulation and lung development by age, gender, and height among children with cystic fibrosis
- Unlocking growth potential: Ivacaftor therapy and developmental gains in lung and height in a cohort study of children and young adults with cystic fibrosis
E.P. Costa
University of Alabama System (US)
2 shared publications
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
- Predicting Cavg of CFTR Modulators Using Sparse Sampling: Evaluating Single and Multiple Time Points with Machine Learning Approaches
Bryan Garcia
1 shared publication
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
Stefanie Krick
Cystic Fibrosis Foundation (US)
1 shared publication
- Pharmacokinetic variability of CFTR modulators from standard and alternative regimens
Similar Researchers
Based on overlapping research topics
Leanne Whiteside Mansell
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Disease Mechanisms Research
Molecular Biology Techniques and Applications
S. Abouelenein
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Disease Mechanisms Research
Pharmacological Effects and Toxicity Studies
Henry F. Simmons
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Disease Mechanisms Research
Pharmacological Effects and Toxicity Studies
Jill E. Hemmati
University of Arkansas at Fayetteville
Metabolism and Genetic Disorders
Disease Mechanisms Research
Pharmacological Effects and Toxicity Studies
L Walters
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Disease Mechanisms Research
Pharmacological Effects and Toxicity Studies
Yuxin Wang
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Disease Mechanisms Research
Pharmacological Effects and Toxicity Studies